Post Brexit Landscape For The Pharmaceutical Industry

In the debut episode of PharmaLex Talks, host Elizabeth Hunt engages in a comprehensive discussion with Charley Maxwell, Director QMC / Senior Consultant at Pharmalex, to delve into the regulatory challenges posed by the post-Brexit pharma landscape. Their conversation spans various critical topics, encompassing the current and anticipated costs of Brexit to the pharmaceutical industry, the foremost challenges that lie ahead, the strategies adopted by UK manufacturers to navigate these hurdles, the implications of the Northern Ireland Protocol, and more.